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Background. Treatment with radiation therapy associated to sparing limb surgery in soft tissue sarcomas has shown a clear beneﬁt
in improving local control and survival in high grade tumors; the best radiation therapy technic is still debating.
Purpose. To evaluate response and toxicity of patients treated with HDR brachytherapy at Navarra Hospital.
Methods. Between2009and2012, 22patientsunderwent spearing limbsurgery andperioperative brachytherapy20Gy in5 fractions
or intraoperative brachytherapy for recurrent disease 10Gy in one fraction; plus adjuvant external beam radiotherapy (EBRT)
50Gy(3D or IMRT) or neoadjuvant 45Gy. Acute and late radiation toxicity was scored by CTCAE v4.0 criteria.
Results. The median age was 57 years. Most of them had adipocitic tumors (27%) followed by ﬁbrohistiocytic (22.7%), ﬁbroblastic
(13.6%), uncertain differentiation (13.6%), peripheral nerves sheath (9.1%), locally aggressive intermediate grade tumors (9.1%)
and leiomyosarcoma (4.5%). The median tumor size was 8.25 cm. 31% were stage IB, 18.2% were IIA and 13.6% III. 73.6% were
located in the lower limbs and 22.7% in the superﬁcial trunk. Brachytherapy: 19 patients perioperative and 3 intraoperative;
20 patients had adjuvant EBRT and 2 neoadjuvant. Acute toxicity grade 2 or superior: 9.1%(2p) had G3 infection, G2 and G4
dehiscence in 4.5% for both, G2 necrosis in 4.5%, G2 haematoma in 4.5%, G2–G3 radiodermitis: 35%. Late toxicity was detected
in 2p: G2 pain 4.5%, lymphedema G2–G3 9.1% and 18.2% respectively, G2 neuritis in 4.5%. Acute or late toxicity did not correlate
with PTV volume neither Homogeneity Index. Only 18% of all patients had local recurrence; 13.6% and 4.5% of them had a second
and third recurrence respectively. Systemic recurrence was seen in 2 patients, one dead by disease. Local disease free survival
at 2 years was 83%.
Conclusion. HDR brachytherapy is a safe procedure with low rate of toxicity even increasing total dose directly in the tumor bed
and shorting whole treatment time.
http://dx.doi.org/10.1016/j.rpor.2013.03.027
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Purpose & objectives. PBI is an alternative modality of treatment suitable for patients with low-risk early breast cancer after
conservative surgery. Herein, we describe the complete procedure for PBI.
Material & methods. A complete description of the implantation, planning and treatment technique for PBI is described based on
a recent case performed in our department. A 78 years old lady underwent on Monday to the operating theatre for implantation,
under local anaesthesia, of 16 wires of 18 cm long, located in 3 planes according to the rules described by the Paris system. After-
ward, steel needles were replaced by plastic tubes and a CT scan of the whole breast for physical planning purpose was acquired.
A total dose of 34Gy was prescribed in 8 fractions of 4Gy, b.i.d. with at least six hours apart between fractions. Brachytherapy
was delivered by using an HDR-Microselectron (Nucletron) afterloader under the radiotherapist supervision. The patient was
in-ward during a whole week. After delivering of the 8th fraction, plastic tubes were removed and the patient was discharged
without any complications.
Results. Rationale for PBI relies on the well-known fact that most of ipsilateral breast local relapses are located on, or in the
immediate vicinity, of the surgical bed. This modality of brachytherapy allow us to reduce total treatment time from the standard
3 weeks to 1 week and contributes to a better quality of life for the patients. However, we only consider PBI for those patients
that meet the GEC-ESTRO criteria of low-risk and therefore suitable for this sort of treatment.
Conclusions. PBI is an attractive alternative to whole breast radiotherapy, especially in those cases of low-risk breast cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.028
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Introduction. The role of brachytherapy (BRT) boost in the management of breast cancer treated conservatively is more than
consolidated.
Objectives. To evaluate our results in terms of toxicity and conﬁrm the hypothesis that it is the same whether the fractionation of
thewhole breast radiotherapy administered previously is conventional (46–50Gy/23–25 sessions) or hypofractionated (40.05Gy/15
sessions).
